Showing results (191-200 of 253) with videos related to

Sort By:
Pageof 26
Frontiers in Genetics|May 5, 2018
A Genome-Wide Linkage Study for Chronic Obstructive Pulmonary Disease in a Dutch Genetic Isolate Identifies Novel Rare Candidate VariantsIvana Nedeljkovic, Natalie Terzikhan, Judith M Vonk, et al.
ERJ Open Research|January 17, 2022
Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based studyElizabeth Benz, Sara R A Wijnant, Katerina Trajanoska, et al.
The Journal of Allergy and Clinical Immunology|May 8, 2016
Asthma inflammatory phenotypes show differential microRNA expression in sputumTania Maes, Francisco Avila Cobos, Florence Schleich, et al.
Respiratory Research|October 31, 2019
Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trialKristina Vermeersch, Ann Belmans, Kris Bogaerts, et al.
The European Respiratory Journal|June 6, 2020
Innate lymphoid cells in isocyanate-induced asthma: role of microRNA-155Evy E Blomme, Sharen Provoost, Erica Bazzan, et al.
Clinical Nutrition ESPEN|May 23, 2017
The effects of lutein on respiratory health across the life course: A systematic reviewDebora Melo van Lent, Elisabeth T M Leermakers, Sirwan K L Darweesh, et al.
Thorax|January 8, 2013
Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trialGuy G Brusselle, Christine Vanderstichele, Paul Jordens, et al.
BMJ Open Respiratory Research|February 27, 2024
Real-world treatment trajectories of adults with newly diagnosed asthma or COPDAniek F Markus, Peter R Rijnbeek, Jan A Kors, et al.
Clinical & Translational Immunology|June 17, 2021
Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary DiseaseEvy E Blomme, Sharen Provoost, Elise G De Smet, et al.
Eclinicalmedicine|January 27, 2025
Roads to remission: evolving treatment concepts in type 2 inflammatory diseasesMarek Lommatzsch, Katharina Blumchen, Lisa A Beck, et al.
Pageof 26